Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results

Chemotherapy

Volumn 60, Issue 5-6, 2015, Pages 294-299

  Zustovich, Fable ^a   Ferro, Alessandra ^a   Lombardi, Giuseppe ^a   Farina, Patrizia ^a   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bevacizumab; Brain metastases; Non small cell lung cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN METASTASIS; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; EMERGENCY SURGERY; FEMALE; HUMAN; HYPERTENSION; LOCAL THERAPY; MALE; MIDDLE AGED; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH PERFORATION; THROMBOCYTOPENIA;

EID: 84929667454     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000376605     Document Type: Article

References (21)

1. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
2. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
3. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
4. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-1809.
5. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP: Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 20-30.
6. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751.
7. Chamberlain MC: Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011; 5: 117-129.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
9. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-5261.
10. Besse B, Le Moulec S, Senellart H, Mazieres J, Barlesi F, Dansin E, Robinot G, Perol M, Moro-Sibilot D, Soria JC: Phase II study of bevacizumab in combination with first-line chemotherapy or second-line erlotinib in non-squamous NSCLC patients with asymptomatic untreated brain metastases (ML21823). Ann Oncol 2012; 23:ix426.
11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
12. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB: Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010; 100: 443-447.
13. Khasraw M, Holodny A, Goldlust SA, DeAngelis LM: Intracranial hemorrhage in patients with cancer treated with bevacizumab: The Memorial Sloan-Kettering experience. Ann Oncol 2012; 23: 458-463.
14. Wang Y, Dong L, Bi Q, Ge X, Zhang X, Wu D, Fu J, Zhang C, Wang C, Li S: Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice. Chemotherapy 2011; 57: 244-252.
15. DeAngelis LM, Mandell LR, Thaler HT, Kimmel DW, Galicich JH, Fuks Z, Posner JB: The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery 1989; 24: 798-805.
16. Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N, Wilson P, Faivre-Finn C, Barton R, Parmar MK, Mulvenna PM: Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-smallcell lung cancer? Clin Oncol 2013; 25:e23-e30.
17. Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM: Venous thromboembolism and cancer: A systematic review. J Thromb Thrombolysis 2010; 30: 67-78.
18. Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C, Pabinger I, Marosi C: Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007; 9: 89.
19. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH: Epidemiology of venous thromboembolism in 9,489 patients with malignant glioma. J Neurosurg 2007; 106: 601.
20. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124.
21. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN; PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecularweight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 1959.